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How can we improve the efficacy of 
palbociclib by combining it with treatments 
that target the S-phase of the cell cycle?
Background and Significance
Medulloblastoma is the most common malignant pediatric brain tumor 
and current surgical, chemotherapeutic, and radiative treatments pose 
the risk of recurrence as well as severe, long-term neurological deficits. 
Because medulloblastoma is a heterogeneous tumor with four distinct 
subgroups, current research involves developing less toxic and more 
personalized therapeutic treatment options.  Palbociclib is a current 
drug used to treat breast cancer, however in order to extend this 
therapeutic treatment to medulloblastoma the blood-brain barrier must 
be considered. To address this physiological barrier, we developed the 
novel nanoparticle formulation of palbociclib (POx-palbo). Mice treated 
with this formulation showed prolonged survival and an early cell-cycle 
arrest of tumor cells in the G1 (growth) phase, but this effect wears off 
by 24 hours. Additionally, monotherapy of POx-palbo fails to cure 
medulloblastoma due to resistance. Thus, combination strategies are 
needed to aid in the increased cell-cycle arrest in medulloblastoma cells 
and target resistance.  Here, we use an OLIG2 inhibitor, CT-179 to 
address both resistance to POx-palbo and increase cell-cycle arrest.
Hypothesis 
In order to investigate the proposed question, we 
hypothesize that that POx-palbo in combination 
with CT-179, an OLIG2 inhibitor, will irreversibly 
arrest the cell-cycle and aid in the therapy of 
medulloblastoma. 
Results: Our results suggest that 
CT-179 combined with POx-palbo 
increases tumor cell cycle arrest by 
halting a higher number of cells in the G0 
(resting) phase than either treatment 
alone (Fig. 1). This combinational effect, 
continues to be statistically significant 
after both 6 and 24 hours, although there 
are fewer cells in the resting phase at the 
longer time point due to decreased 
efficacy of POx-palbo at this stage. 
Overall, this treatment method continues 
to be promising because it targets 
resistant tumor cells, pushing a higher 
number into cell cycle arrest. 
Figure 1. Combinational treatment at 6 hours shows significantly 
more tumor cells halted in the G0 phase than CT-179 and 
POx-palbo alone. This remains true for the 24 hour time point, but 
there are fewer halted cells due to decreased POx-palbo efficacy at 
24 hours. The arrows indicate an increase or decrease in cell cycle 
occupation compared to the saline control. 
Importance: These results are extremely relevant to the scientific community because they show that 
combinational drug therapies are useful treatment plans to combat drug resistance. Speaking to the general 
audience, current chemotherapeutic and radiative treatments for pediatric brain tumors result in neurological 
trauma that leads to deficits and developmental delays. Finding less intensive, but ultimately more effective 
treatment plans is of the utmost importance to saving children’s lives and improving future well-being. 
